<DOC>
	<DOCNO>NCT01918839</DOCNO>
	<brief_summary>This clinical trial intend evaluate efficacy safety injection VINCI Plus compare Restylane-LÂ® correction nasolabial fold .</brief_summary>
	<brief_title>Efficacy Safety Injection With VINCI Plus Hyaluronic Acid Filler</brief_title>
	<detailed_description />
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Male female age 3065 , point screening , wrinkle side treatment area ( nasolabial fold ) 3rd 4th level WSRS ( Wrinkle Severity Rating Score ) Surrounding soft tissue wrinkle side nose lip sag Wrinkles side nose lip visually symmetric Agrees stop treatment facial wrinkle improvement include dermatology treatment clinical trial Able understand follow instruction participate entire period clinical trial Subject voluntarily agree participate clinical trial give inform write consent At point screening , intradermal test result show skin irritation medical device clinical trial Within 2 week date screening , subject take antithrombotic ( exception low dose aspirin 100mg , 300mg/day ) nonsteroidal antiinflammatory medication Case subject abnormal liver function blood coagulation , take antithrombotic medication ( exception low dose aspirin 100mg , 300mg/day ) clinical trial Subject use facial topical liniment ( steroid , retinoids : exclude medicine cosmetic ) within 4 week date screening plan continue use facial topical liniment clinical trial Within 6 month date screening , subject receive antiwrinkle acne treatment Within 6 month date screening , subject receive facial microdermabrasion treatment , skin regeneration/rejuvenation treatment , plastic surgery , cosmetic surgery ( include Botox injection ) Within 1 year date screening , subject receive CaHA ( Calcium Hydroxyapatite ) treatment clinical trial medical device treatment area Subject cure facial gel ( Softform ) silicone implant inserted permanent facial expansion Within 1 year , subject illness cause scar scar clinical trial medical device treatment area Subject facial skin disease skin wound infection affect clinical trial Weak immune system suspect immune system weak History anaphylaxis severe allergic complexity History hypertrophic scar keloid In past , adverse effect EMLA Cream ( EMLA Cream use , exclusion criterion subject applicable ) History hypersensitivity Lidocaine Cardiovascular , digestive , respiratory , endocrine , central nervous system disorder seem clinically significant mental illness significant impact previous clinical trial currently mental illness Within 30 day screen , subject participate clinical trial Female subject childbearing potential agree medically accept method contraception period clinical trial Medically acceptable method contraception : condom ; oral contraception continue least three month ; intrauterine use , instal contraceptive device Pregnant woman nurse mother In addition , test director person charge medically judge clinically significant finding improper clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Investigational Device ( VINCI Plus )</keyword>
	<keyword>Correction nasolabial fold</keyword>
	<keyword>Wrinkle improvement</keyword>
	<keyword>Wrinkle correction</keyword>
</DOC>